References
- Clyman RI. Ibuprofen and patent ductus arteriosus. N Engl J Med 2000;343:728–730.
- Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics 2010;125:1020–1030.
- Itabashi K, Ohno T, Nishida H. Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin. J Pediatr 2003;143:203–207.
- Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2010;14:CD003481.
- Gournay V, Roze JC, Kuster A, Daoud P, Cambonie G, Hascoet JM, Chamboux C, et al. Prophylactic ibuprofen versus placebo in very premature infants: A randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1939–1944.
- Sperandio M, Beedgen B, Feneberg R, Huppertz C, Brüssau J, Pöschl J, Linderkamp O. Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation. Pediatrics 2005;116:1361–1366.
- Jegatheesan P, Ianus V, Buchh B, Yoon G, Chorne N, Ewig A, Lin E, et al. Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: A multicenter, randomized, controlled trial. J Pediatr 2008;153:183–189.
- Desfrere L, Zohar S, Morville P, Brunhes A, Chevret S, Pons G, Moriette G, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 2005;30:121–132.
- Hirt D, Van Overmeire B, Treluyer JM, Langhendries JP, Marguglio A, Eisinger MJ, Schepens P, Urien S. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol 2008;65:629–636.
- Van Overmeire B, Touw D, Schepens PJ, Kearns GL, van den Anker JN. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther 2001;70:336–343.